Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Pacific Biosciences of California's Marketable Securities for the quarter that ended in Jun. 2026 was MXN3,069 Mil.
Pacific Biosciences of California's annual Marketable Securities
declined
from Dec. 2023 (MXN7,664 Mil) to Dec. 2024 (MXN6,978 Mil) and
declined
from Dec. 2024 (MXN6,978 Mil) to Dec. 2025 (MXN3,886 Mil).
Pacific Biosciences of California (MEX:PACB) Marketable Securities Explanation
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Pacific Biosciences of California Marketable Securities Related Terms
Pacific Biosciences of California Marketable Securities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Marketable Securities Chart
What does a Marketable Securities of MXN3,069 Mil mean?
Pacific Biosciences of California (MEX:PACB) has a Marketable Securities of MXN3,069 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Marketable Securities too high?
Pacific Biosciences of California's current Marketable Securities is MXN3,069 Mil. Overall, Pacific Biosciences of California has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Marketable Securities compare to DCTH and CLPT?
Pacific Biosciences of California's Marketable Securities of MXN3,069 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Marketable Securities is MXN3,069 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Pacific Biosciences of California (MEX:PACB) has a current Marketable Securities of MXN3,069 Mil. The stock's GF Value™ is MXN35.24, compared to a current price of MXN27.50 — trading 22% below its estimated fair value. The current Marketable Securities is MXN3,069 Mil. Pacific Biosciences of California's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Pacific Biosciences of California (MEX:PACB), the current Marketable Securities is MXN3,069 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (MEX:PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of MXN27.50 is trading 22% below its estimated GF Value™ of MXN35.24.
Key valuation signals for MEX:PACB:
Marketable Securities: MXN3,069 Mil
GF Value™: MXN35.24 vs. price of MXN27.50 (22% below fair value)
No single metric tells the full story. See the MEX:PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
58GF Score
Get the complete analysis for MEX:PACB
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PACB has been successfully added to your 
